What are the indications, dosing, contraindications, monitoring requirements, side effects, and alternative therapies for ezetimibe?

Ezetimibe: Comprehensive Clinical Guide

Ezetimibe is a well-tolerated, first-line add-on therapy to statins for LDL-cholesterol lowering, with proven cardiovascular benefit and an excellent safety profile. 1

Mechanism of Action

Ezetimibe inhibits the NPC1L1 protein in the small intestine, reducing cholesterol absorption. This mechanism is synergistic with statins, which inhibit hepatic cholesterol synthesis, providing complementary LDL-C reduction. 1

FDA-Approved Indications

Ezetimibe is indicated as adjunct to diet for: 2

• Primary hyperlipidemia: Alone or combined with statins to reduce total cholesterol, LDL-C, ApoB, and non-HDL-C in adults and pediatric patients ≥10 years
• Heterozygous familial hypercholesterolemia (HeFH): Combined with statins in adults and children ≥10 years
• Homozygous familial hypercholesterolemia (HoFH): Combined with atorvastatin or simvastatin in adults and children ≥10 years
• Mixed hyperlipidemia: Combined with fenofibrate
• Homozygous sitosterolemia: To reduce sitosterol and campesterol in adults and children ≥9 years

Dosing

Standard dose: 10 mg orally once daily, with or without food 1, 2

Important Timing Considerations:

• When combined with bile acid sequestrants (BAS): Take ezetimibe ≥2 hours before OR ≥4 hours after the BAS 1, 2
• Assess LDL-C as early as 4 weeks after initiation 2

Expected LDL-C Reduction:

• Monotherapy: 18% reduction 1
• Combined with statin: Additional 25% incremental reduction (13-20% beyond statin alone) 1, 3

Contraindications

Absolute contraindications: 2

1. Hypersensitivity to ezetimibe or any excipient (including anaphylaxis, angioedema, rash, urticaria)
2. When combined with other agents: Contraindicated if the combination drug (statin, fenofibrate) is contraindicated in that patient

Key Clinical Caveat:

Not recommended in moderate-to-severe hepatic impairment 1

Monitoring Requirements

Monitor hepatic transaminases (ALT/AST): 1, 2

• Perform liver enzyme testing before initiation when used with statins
• Monitor during treatment based on statin monitoring recommendations
• Consider withdrawal if ALT or AST ≥3× ULN persist
• This is particularly important when combined with statins, as persistent elevations can occur

Monitor for myopathy/rhabdomyolysis: 1, 2

• Assess for muscle symptoms (pain, weakness, tenderness)
• Most cases of rhabdomyolysis occurred with concomitant statin or fibrate use
• Discontinue immediately if myopathy suspected

Side Effects

Common Adverse Effects (≥2% incidence):

Monotherapy: 1

• Upper respiratory tract infection
• Diarrhea
• Arthralgia
• Sinusitis
• Pain in extremities
• Fatigue
• Influenza

Combined with statin: 1

• Nasopharyngitis
• Myalgia
• Upper respiratory tract infection
• Arthralgia
• Diarrhea
• Back pain

Serious but Rare:

• Myopathy and rhabdomyolysis: Rare, but reported both as monotherapy and with statins 1, 4
• Hepatic transaminase elevations: Primarily when combined with statins 1

The safety profile is excellent overall, with adverse effects being few and mild in most studies 4

Drug Interactions

Clinically significant interactions: 1, 2

1. Cyclosporine: Increases exposure of both ezetimibe and cyclosporine—monitor cyclosporine concentrations closely
2. Fibrates:
   • Combination with fibrates other than fenofibrate is not recommended
   • With fenofibrate: Monitor for cholelithiasis; if suspected, obtain gallbladder studies and consider alternative therapy
3. Bile acid sequestrants: Decrease ezetimibe exposure—use proper timing (≥2 hours before or ≥4 hours after BAS)

Minimal CYP450 interactions: Ezetimibe is eliminated primarily by glucuronidation, not CYP oxidation, resulting in fewer drug interactions compared to statins 5

Special Populations

Pregnancy/Lactation: 1, 2

• Avoid use—no safety data in humans
• Discontinue when pregnancy is recognized unless benefits clearly outweigh risks

Elderly (≥75 years):

• The EWTOPIA 75 trial demonstrated cardiovascular benefit in patients ≥75 years without prior coronary disease 6
• Cholesterol absorption efficiency increases with age, making ezetimibe particularly effective in older adults
• May be preferred over high-dose statins in elderly due to better tolerability

Cardiovascular Outcomes Evidence

Ezetimibe has proven cardiovascular benefit in two major trials: 1

1. IMPROVE-IT: Addition of ezetimibe to moderate-intensity statin in patients with recent acute coronary syndrome:

   • Reduced composite endpoint (CV death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, nonfatal stroke)
   • Median follow-up: 6 years

2. SHARP: Simvastatin plus ezetimibe in patients with chronic kidney disease:

   • Reduced first major ASCVD event (nonfatal MI, CHD death, nonhemorrhagic stroke, arterial revascularization)
   • Median follow-up: 4.9 years

Alternative and Complementary Therapies

When ezetimibe is insufficient or not tolerated: 1, 7, 3

First-line alternatives:

1. PCSK9 inhibitors (alirocumab, evolocumab):

   • For very high-risk patients with LDL-C ≥70 mg/dL despite maximal statin + ezetimibe
   • Provide 43-64% additional LDL-C reduction
   • More expensive, require prior authorization

2. Bempedoic acid:

   • Alternative for statin-intolerant patients
   • 17-18% LDL-C reduction as add-on to statin
   • Combined bempedoic acid/ezetimibe: 38% reduction

3. Bile acid sequestrants:

   • 15-30% LDL-C reduction
   • Limited by GI side effects and drug interactions
   • Not absorbed systemically

Clinical Algorithm for LDL-C Management:

Step 1: Maximize statin therapy (high-intensity if tolerated)

Step 2: If LDL-C remains elevated, add ezetimibe 10 mg daily 7, 3

• Target: LDL-C <70 mg/dL for very high-risk patients
• Target: LDL-C <100 mg/dL for high-risk patients

Step 3: If LDL-C ≥70 mg/dL despite statin + ezetimibe in very high-risk patients, add PCSK9 inhibitor 7

Alternative pathway: For statin-intolerant patients:

• Try ezetimibe monotherapy first
• Consider bempedoic acid or combination bempedoic acid/ezetimibe
• PCSK9 inhibitors if targets not met

Key Clinical Advantages

Ezetimibe is generally well tolerated and generic is available 1

1. Excellent safety profile: Similar to placebo in most studies 4, 5
2. Convenient oral dosing: Once daily, with or without food
3. Cost-effective: Generic formulation available
4. Allows lower statin doses: Reduces statin-related side effects while maintaining efficacy 8, 9
5. Proven cardiovascular benefit: Not just surrogate endpoint improvement 1
6. Useful in statin intolerance: Effective monotherapy option 8, 10

Common Pitfalls to Avoid

1. Timing with bile acid sequestrants: Failure to separate administration by ≥2 hours reduces ezetimibe absorption
2. Inadequate monitoring: Must monitor liver enzymes when combined with statins
3. Overlooking in elderly: Particularly effective in patients ≥75 years due to increased cholesterol absorption with age
4. Premature escalation to expensive therapies: Ezetimibe should be tried before PCSK9 inhibitors in most patients
5. Ignoring combination with fenofibrate: Monitor for gallstones when using this combination